Sera Prognostics (SERA) announced the pricing of its underwritten public offering of 1.25M shares of its Class A common stock at a public

The firm plans to use the proceeds to support commercial expansion in the US and EU, and for research, potential regulatory submissions, and general corporate purposes.

Jefferies, TD Cowen and William Blair are acting as joint book-running managers and RBC Capital Markets is acting as a bookrunner for the proposed offering. Sera intends to use the net proceeds from the proposed offering to expand its commercial infrastructure and capabilities in the United States,

Sera Prognostics (SERA) announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of

Sera Prognostics, a company specializing in high-value women's health diagnostics with a market capitalization of $134 million, has seen its stock price touch a 52-week low, trading at $3.84. According to InvestingPro data,

SALT LAKE CITY - Sera Prognostics, Inc. (SERA), a company specializing in pregnancy biomarker information, has initiated a public offering of its Class A common stock and pre-funded warrants. The offering includes an additional option for underwriters to purchase up to 15% more shares.